Navigation Links
Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
Date:7/15/2008

se rate (CR) of 41 percent. A CR means that after treatment with the TREANDA and rituximab combination, patients had no detectable evidence of disease. These responses were durable, with a median duration of 21 months overall (19 months for the mantle cell population). Additionally, the combination of TREANDA and rituximab was associated with progression-free survival (PFS) of 23 months overall and for patients with mantle cell lymphoma.

In this published study, the combination of both treatments was generally well tolerated. The most common adverse events in the trial included myelosuppression (a condition in which bone marrow activity is decreased), nausea, infection, fatigue, constipation, and diarrhea.

This combination study is one of three studies in patients with NHL that Cephalon submitted to the FDA in December 2007 requesting approval of TREANDA for the treatment of patients with indolent NHL who have progressed during or following treatment with rituximab or a rituximab-containing regimen. The other two studies evaluated the efficacy and safety of TREANDA as monotherapy in this patient population. In all three studies, patients treated with TREANDA had a high rate of response and a manageable side effect profile, with myelosuppression as the most common side effect. Cephalon anticipates a review decision on this application by the agency by October 31, 2008.

About Non-Hodgkin's Lymphoma

According to the American Cancer Society, an estimated 66,000 people in the United States will be diagnosed in 2008 with NHL. There are approximately 30 different types of NHL, which have been divided into two major categories: indolent (or slow growing) and aggressive. Indolent B-cell lymphoma and mantle cell lymphoma (one of the more aggressive sub-types) are difficult to treat because patients are prone to relapse after treatment.

About TREANDA

TREANDA has a unique chemical structure with two primary components, an alkylating gro
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
2. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
3. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
4. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
5. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
8. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
9. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
10. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
11. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014 GenomeDx Biosciences today ... the American Society for Radiation Oncology (ASTRO) Annual ... Cancer Classifier, a genomic test capable of predicting ... and improve patient outcomes for prostate cancer patients ... a recently published study that demonstrates how Decipher ...
(Date:9/15/2014)... -- Patients in today,s changing health care landscape are receiving ... setting versus a hospital. In an effort to stay ... continue to receive high quality medical care; Kaiser Permanente ... medicine residency program. The program,s progressive curriculum will prepare ... even virtual settings. "We are excited ...
(Date:9/15/2014)... 15, 2014 /PRNewswire-iReach/ -- On September 8, 2014, ... Carolina, submitted a Citizen Petition to Dr. ... to add another Black Box Warning to Levaquin, ... asks for a Black Box Warning for the ... suicidal thoughts or acts, loss of consciousness, delirium, ...
Breaking Medicine Technology:Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 2Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 3Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 2Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 3
... Calif. , May 6 Questcor Pharmaceuticals, Inc ... trading of Questcor,s common stock pending news. The Peripheral and Central ... Administration (FDA) meets today to review and discuss the Company,s supplemental ... injection) for the treatment of infantile spasms. , ...
... May 5 ViaCyte, Inc., a preclinical stage stem cell engineering company focused ... , , ... Patent 7,695,963, entitled "Methods for Increasing Definitive Endoderm Production".  Methods described in this patent ... it. , , , ...
Cached Medicine Technology:Trading Halted Today in Questcor Pharmaceuticals Common Stock 2ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes 2
(Date:9/15/2014)... Today, Zane Benefits, the #1 Online Health Benefits Solution, ... show. , According to Zane Benefits, health insurance ... make sense to choose a “one size fits all” ... employee as much as 60 percent on health insurance ... on Business , Chris Redgrave, highlights the rising costs ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 The ... & World Report consists of seven hospitals using OnBase ... Hopkins Hospital and Cleveland Clinic were ranked at the ... spots respectively. The rankings cover nearly 5,000 medical centers ... of 17 hospitals that scored highest in at least ...
(Date:9/15/2014)... (HealthDay News) -- U.S. heart experts recommend doctors use ... evaluating young people for underlying heart disease that could ... Association and the American College of Cardiology said in ... family medical history along with a physical examination can ... from birth) risks for sudden cardiac death. ...
(Date:9/15/2014)... DALLAS, TX September 12, 2014 - An estimated ... disorder (PTSD) at some point during their lifetime. Brought ... PTSD is the result of altered chemistry and physiology ... a normal brain versus one altered by PTSD is ... from the Center for BrainHealth at The University of ...
(Date:9/15/2014)... Palo Alto, CA (PRWEB) September 15, 2014 ... seventh anniversary since its founding in 2007. To mark ... the local community for supporting the village and helping ... Village provides a safe, secure and fun community for ... connected to the community and live in their own ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Featured on Zions Bank Speaking on Business 2Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:EEG study findings reveal how fear is processed in the brain 2Health News:Avenidas Village Celebrates Anniversary 2
... Due to New PhRMA Marketing Regulations and Converging ... are taking on the 2009 PhRMA code with ... company whose integrated engagement solutions have been generating ... past two years the company has helped brands ...
... /PRNewswire/ -- Akerman Senterfitt, one of the ... top 100 firms in the U.S., today announced that ... the auspices of the American Health Lawyers Association (AHLA) ... and issues concerning privilege and confidentiality. The live audiocast ...
... SGP ) is scheduled to announce its sales ... year on Tuesday, Feb. 3, 2009. At 8 a.m. ... to review results for the 2008 fourth quarter and full ... members of management will host the conference call. To listen ...
... 6 Elsevier, the world,s,leading publisher of ... announced today that fifty prestigious titles from ... on ScienceDirect, its online,scientific research platform. , ... Spanish language medical publisher acquired by,Elsevier in ...
... these cold, snowy monthsROSEMONT, Ill., Jan. 6 ... inside with a blanket and a good book -- ... whole new excitement of sports and outdoor activities for ... ( http://orthoinfo.aaos.org/topic.cfm?topic=A00321 ), snowboarding and other cold-weather activities are ...
... North America of,Charlotte, NC, announces the completion of ... provider of support services operating,mainly in the business ... wholly owned subsidiary of Compass Group North America ... America focused on delivering,support services to the business ...
Cached Medicine News:Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 2Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 3Health News:Akerman Senterfitt Hosts National Panel Discussion on Patient Safety Organizations 2Health News:Akerman Senterfitt Hosts National Panel Discussion on Patient Safety Organizations 3Health News:Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings 2Health News:Elsevier to Include Doyma Spanish Medical Collection Titles on ScienceDirect 2Health News:Elsevier to Include Doyma Spanish Medical Collection Titles on ScienceDirect 3Health News:Skate Through Winter Sports Injury-Free 2Health News:Skate Through Winter Sports Injury-Free 3Health News:Compass Group North America Acquires KIMCO Corporation 2
The Marco E-Z Tilt Chair combines the most simplified manual reclining motion with a new modern, sophisticated appearance....
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
Medicine Products: